Thursday, January 26, 2012
Gilead Sciences Inc., of Foster City, Calif., said it started a Phase II trial of GS-7430, a prodrug of tenofovir, the active agent in Viread (tenofovir disoproxil fumarate), in HIV-1 infection in treatment-naïve adults. The study will evaluate GS-7340 as part of a once-daily, co-formulated single-tablet regimen that will also contain the boosting agent cobicistat, the integrase inhibitor elvitegravir and Emtriva (emtricitabine) and will compare that regimen to Gilead's Quad single-tablet regimen containing Viread and Emtriva (as Truvada), elvitegravir and cobicistat.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.